The funding round is intended for the adaptation of the in vitro diagnostic kit – IMMUNOBIOGRAM® (currently tested under a clinical trial with renal transplanted patients) for application in the field of Rheumatoid Arthritis.
The company’s pre-money valuation is 8,200,000 euros and it offers an exit in 2027 with ROE estimated at 508.72% and TAE at 45.41%.
The kit will generate to Biohope revenues estimated in € 7.6 M in 2025 and € 32.2 M in 2027.
Biohope, a Spanish biotech company focused on the development of diagnostic tools for the personalization of treatments in chronic inflammatory diseases, have just launched a crowdfunding campaign to raise 350,000 euros for the adaptation of the IMMUNOBIOGRAM® kit to treatment selection in Rheumatoid Arthritis.
This kit has been initially developed to personalize the immunosuppressive treatment in renal transplantation and, through a small technological adaptation, it will be useful in the field of Arthritis. At present, public health in Europe allocates 73 billion euros annually in patients suffering from rheumatoid arthritis. A disease suffered by 1% of the world’s population. This kit will optimize the treatment and it is estimated that it will reduce the associated costs up to 50%.
The project commercialization will generate to Biohope licensing incomes, considering royalties from both kidney transplant and rheumatoid arthritis projects, estimated in € 7.6m in 2025 and € 32.2m in 2027. With a pre-money valuation of € 8,200 .000 euros, the company offers investors an exit in 2027 with estimated ROE of 508.72% and APE of 45.41%.
An exit can also be offered in 2020 with an estimated ROE of 121.28% and an APR of 10.64%, but due to the nature of the company activity, Biohope advise to exit in 2027 when higher profitability is expected from the licensing of the Rheumatoid Arthritis project to a pharma company.